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Prompt linkage to human immunodeficiency virus 
(HIV) care after diagnosis is crucial to ensure opti-
mal patient outcomes. However, few countries moni-
tor this important public health marker and different 
definitions have been applied, making country and 
study comparisons difficult. This article presents an 
expert-agreed, standard definition of linkage to care 
for a pragmatic approach to public health monitoring, 
appropriate to the European context. Here, linkage to 
care is defined as patient entry into specialist HIV care 
after diagnosis, measured as the time between the HIV 
diagnosis date and one of the following markers: either 
the first clinic attendance date, first CD4+ cell count or 
viral load date, or HIV treatment start date, depending 
on data availability; Linkage is considered prompt if 
within 3 months of diagnosis. Application of this defi-
nition by researchers and public health professionals 
when reporting surveillance or research data relating 
to linkage to care after HIV diagnosis will enable reli-
able comparisons across countries, better assessment 
of the success of health services programmes aimed 
at improving peoples access to HIV treatment and care 
and the identification of barriers limiting access to HIV 
care across Europe.
Background
Optimal health outcomes for people with human immu-
nodeficiency virus (HIV) are dependent on diagnosis 
early in infection, prompt linkage to HIV services after 
diagnosis, engagement and retention in care and ini-
tiation of and adherence to antiretroviral therapy (ART) 
[1,2]. Late diagnosis of HIV and delays in accessing 
care and treatment continue to be associated with high 
mortality rates among people with HIV, particularly in 
the first year of diagnosis [3].
Public health monitoring of the HIV patient pathway, or 
continuum of care, is essential to ensure missed oppor-
tunities are identified and gaps closed [4]. Research 
from Europe has focussed on the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) 90–90–90 targets 
[5], producing comparable measures for the propor-
tion of people infected with HIV that are diagnosed, on 
treatment and virally suppressed [6].
However, there are little European data available on 
linkage to HIV care after diagnosis. A 2014 survey of 
European countries found there to be little agreement 
across countries in how to define linkage to care [4]. 
This lack of consensus is also reflected in the litera-
ture from Europe, in which a variety of definitions of 
linkage to care have been applied, making it difficult 
to compare across studies [7]. The use of a standard 
definition would be helpful to more effectively monitor 
entry into HIV care and facilitate comparisons across 
countries and populations, target interventions and 
identify people most at risk of delaying access to care.
In May 2015, the World Health Organization (WHO) 
released strategic information guidelines to con-
solidate key indicators to monitor the public health 
response to HIV [8]. These guidelines recommended 
that linkage to care be defined as the duration of time 
starting with HIV diagnosis and ending with enrolment 
in HIV care or treatment. However, this definition was 
ambiguous as to what data could be used to populate 
the linkage indicator and made no recommendations in 
what time period to use to define prompt linkage.
Proposed definition
As part of the Second Health Programme, the European 
Commission co-funded the Optimising testing and 
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linkage to care for HIV across Europe (OptTEST) pro-
ject, with an aim to optimise testing and linkage to 
care for HIV in Europe through a series of work pack-
ages [9]. In September 2015, OptTEST hosted a work-
shop on standardising the linkage to care indicator at a 
wider expert meeting on the continuum of care hosted 
by the European Centre for Disease Prevention and 
Control (ECDC) [10]. The meeting was attended by 48 
experts from 20 countries, including HIV surveillance 
leads from the European HIV Surveillance Network and 
representatives from European HIV patient cohorts. A 
full list of attendees can be found in the Supplement. 
Workshop discussions resulted in experts advocating 
for a pragmatic approach to monitoring linkage to care 
in Europe.
The WHO definition was endorsed and further opera-
tionalised, with linkage to care defined as patient entry 
into specialist HIV care after diagnosis, measured as 
the time between the HIV diagnosis date and either 
the first clinic attendance date, first CD4+ count or viral 
load date, or HIV treatment start date, depending on 
data availability. While, first clinic date after diagnosis 
was considered the gold standard marker for linkage to 
care, experts agreed that for many countries, routine 
baseline laboratory data, such as first CD4+  and viral 
load date, would be practical proxies for care entry. 
The WHO currently recommends CD4+  and viral load 
testing to be carried out at baseline for all newly diag-
nosed persons at the first clinic visit [11]. Treatment 
initiation was included as a marker for care to acknowl-
edge the change in guidelines that state people diag-
nosed with HIV should start ART as soon as possible, 
regardless of CD4+  count, for optimal outcomes [12]. 
In addition, some countries in Europe with limited 
surveillance may not be able to collect bio-marker or 
clinic data but may have information on ART initiation 
linked to external funding for national treatment pro-
grammes. For countries with available data on multiple 
care indicators, first clinic date was preferred, followed 
by CD4+  count date, viral load measurement date and 
finally, treatment start date.
Table
Number of new human immunodeficiency virus (HIV) diagnoses made in 2014 and data availability to monitor subsequent 
HIV care at a national level, European Union and European Economic Area countries, September 2016 (n = 24 countries)
Country New HIV diagnoses in 2014a Care attendance CD4+ count Viral load ART initiation
Belgium 1,050 NC NC NC NC
Croatia 92 √ √ √ √
Cyprus 56 x √ √ √
Czech Republic 232 √ √ √ x
Denmark 256 x √b X x
Estonia 291 x √ X x
Finland 181 x √b X x
France 5,653 x √ √ x
Germany 3,500 x √ √ x
Greece 761 x √ X x
Irelandc 363 x √b √b x
Italy 3,850 x √ √ x
Latvia 347 x √ X x
Lithuania 141 x √b √b √b
Luxembourg 74 √ √ √ √
Malta 40 √ √ √ x
The Netherlands 881 √ √ √ √
Norway 267 x x X x
Poland 1,133 x x X x
Portugal 1,109 x √b √b x
Romania 825 √ √ √ √
Slovenia 49 x √ X x
Spain 4,140 x √ X x
UK 6,157 √ √ √ √
NC: Not complete (country responded to other parts of survey but did not complete data table); √: data available; x: no data available; UK: 
United Kingdom.
a Data from ECDC [26].
b No date information collected.
c Data on ART initiation and CD4+ and viral load dates collected from 2015 onwards.
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There was also discussion at the workshop around 
the accuracy of care indicator dates. It was recognised 
that the dates captured by surveillance systems across 
Europe vary and this may influence linkage calcula-
tions. Where possible, care attendance date should be 
captured as the date of first visit to the HIV specialist 
care provider, regardless of visit purpose. CD4+  and 
viral load dates should be the date that the patient 
blood sample was taken for testing at the specialist 
clinic. ART initiation date should reflect the clinic visit 
at which patients were first prescribed ART.
Prompt linkage to care was defined by experts as 
linkage to care within 3 months of diagnosis, in-line 
with guidance from the United States (US) Centers for 
Disease Prevention and Control (CDC) [13]. The deci-
sion to recommend a 3 month cut-off in Europe was 
based on research from the US showing that initiation 
of care within 3 months of HIV diagnosis is signifi-
cantly associated with faster time to viral suppression 
[2]. Furthermore, data from the United Kingdom show 
that >95% of people diagnosed with HIV enter care 
within 3 months of diagnosis [14] and a 3 month cut-off 
has been used widely in the literature from Europe [7].
Developmental approach
The expert-agreed definition of linkage to care utilises 
a number of markers to signify entry into HIV care, 
acknowledging that there are disparate models of 
care across Europe and data used to calculate linkage 
are captured to varying extents by different countries 
[15,16].
In 2016, a survey was developed as part of the OptTEST 
project, in collaboration with international experts 
from the ECDC, the WHO Regional Office for Europe, 
the HIV/AIDS Civil Society Forum, the EURO HIV EDAT 
(Operational knowledge to improve HIV early diagnosis 
and treatment among vulnerable groups in Europe) pro-
ject, the European AIDS Treatment Group, and national 
experts from Public Health England and AIDS Fondet. 
The 30 national surveillance contact points for HIV in 
the European Union/European Economic Area (EU/
EEA) were identified and invited to take part. The main 
objectives were to assess variables collected at the 
national level that could be used to monitor linkage to 
care, identify data caveats and receive feedback on the 
proposed definition. National data on diagnoses of HIV 
made between 2010 and 2014 were requested, along-
side the proportion of those diagnoses that had entry 
marker data available ever after diagnosis and within 
3 months of diagnoses (e.g. the proportion of people 
with a viral load available).
Responses were received from 24 (80%) of 30 EU/EEA 
national contact points (Table). Nineteen countries pro-
vided data on the number of new HIV diagnoses with 
at least one marker indicating subsequent care. Four 
countries commented on data availability but did not, 
or were not able, to provide data. Taking into account 
both the submitted data and narrative responses, 
linkage to care should be able to be calculated using 
the time difference between diagnosis date and (i) 
care attendance date in seven countries (ii) CD4+ date 
in 16 countries, (iii) viral load date in 11 countries and 
(iv) treatment initiation in six countries. Five countries 
collected markers of linkage to care but not the marker 
date, allowing calculation of the proportion ever linked 
to care but not the timeliness of linkage. The number 
of new HIV diagnoses in 2014 has been included 
in  Table  to show the relative size of the epidemics in 
each country, in the absence of prevalence data.
The majority of countries not able to provide attend-
ance or treatment data, cited problems with either the 
variable not being collected at all (attendance date: 
n  =  9; treatment start: n  =  10) and/or data not being 
reported centrally (attendance date: n = 14; treatment 
start: n = 12). The most common reasons for difficulty 
in providing CD4+information was incomplete report-
ing to national surveillance by clinicians (n  =  8) and 
when data were provided, significant reporting delay 
(n  =  3). Viral load was more difficult to report than 
CD4+ because of a lack of centralised data collection 
mechanisms (n  =  8). There were a few countries that 
reported issues collecting longitudinal patient data 
after diagnosis as care data were either housed in a 
separate clinical cohort database rather than collected 
as part of national surveillance (n = 3) or there was no 
legal framework for collection (n = 6).
Discussion and conclusions
The expert-agreed definition of linkage to care pre-
sented here provides a pragmatic approach to the 
public health monitoring of this key HIV indicator that 
is appropriate to the European context. Linkage to 
care should be defined as patient entry into special-
ist HIV care after diagnosis, more specifically, the time 
between the HIV diagnosis date and either the first clinic 
attendance date, first CD4+ count, viral load date, or HIV 
treatment start date, with prompt linkage measured 
within 3 months. The application of this definition by 
researchers and public health professionals alike when 
reporting surveillance or research data relating to 
linkage to care after HIV diagnosis will enable reliable 
comparisons across countries, studies, population 
groups and allow monitoring of changes in linkage to 
care over time. The identification of gaps in linkage to 
care will allow for better insight into the barriers that 
may currently be limiting access to HIV medical care 
across Europe.
In order to apply this definition, national public health 
agencies and institutions should ensure adequate cap-
ture of clinical data on HIV diagnosis and entry in to 
care, such as CD4+ cell count. Of the 24 countries who 
responded to the survey, 16 could adopt this definition 
given their current national HIV surveillance system. 
However, eight reported poor completion rates of care 
marker data and 14 reported issues with collecting data 
centrally, which may require additional resources and 
time. An analysis of European HIV surveillance data 
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revealed that even CD4+  data, which was considered 
the most appropriate indicator of linkage to care by EU/
EEA countries, was only complete for ca 46% of new 
HIV diagnoses in the WHO European Region reported 
to the ECDC/WHO [17].
To determine the extent to which this expert definition 
is already being used in Europe, a systematic review 
of the literature was carried out in February 2017 [18]. 
Results indicate that 24 studies used the agreed defi-
nition to calculate linkage to care. Of the 22 that pre-
sented estimates, only 14 used a 3 month cut-off for 
prompt linkage. However, this definition and cut-off 
has also been applied to US, Canadian and Australian 
data [19]. To explore barriers to national monitoring of 
linkage to care using this definition and better under-
stand the context within which linkage occurs, OptTEST 
organised meetings in collaboration with local part-
ners in Greece, Poland and Portugal, bringing together 
key stakeholders from government, public health, 
community organisations and HIV care centres. These 
meetings highlighted the variability in the way HIV care 
and HIV surveillance systems are structured in each 
country [20-22], which is reflected in the flexibility in 
care markers used in the expert-agreed linkage to care 
definition.
The ability to calculate linkage to care also depends 
on robust reporting of date of HIV diagnosis. Although 
in discussion at the expert workshop, the importance 
of capturing data on a patient’s first reactive test was 
highlighted, it was recognised that the most practical 
date of diagnosis is the date the laboratory sample was 
taken for confirmatory HIV testing.
It is important to acknowledge that the agreed defini-
tion presented here is most appropriate for monitoring 
linkage to care at a national or clinic level and poten-
tially less applicable to local community testing facili-
ties. Also, co-funded by the European Commission, the 
Euro HIV EDAT project defined linkage to care as: ‘entry 
into health care or follow-up by an HIV specialist or in 
an HIV-unit after a reactive or confirmatory HIV test at 
a community testing facility.’ [23] Researchers found 
that though this was the most practical definition, 
community testing organisations across Europe face 
problems obtaining reliable information on whether a 
patient was successfully linked to care because of con-
fidentiality and data protection issues. Often reporting 
of linkage is informal and limited date information is 
collected [23,24].
In conclusion, adoption of the expert-agreed defi-
nitions of linkage to care and prompt linkage pre-
sented here is needed to ensure consistent monitoring 
of the equitable access to HIV care and treatment. 
Application of a standard definition will help to better 
to understand time trends and to identify and compare 
populations most at risk of not attending for HIV care 
after diagnosis across Europe. The ECDC and the WHO 
Regional Office for Europe should continue to work 
with European countries to improve reporting of link-
age to care data for public health monitoring. In addi-
tion, collaboration between public health bodies and 
national HIV clinical cohorts should be strengthened to 
address gaps in care data availability [25].
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